Treatment of borderline personality disorder is multimodal, involving psychotherapy and prescription pharmacotherapy. Prescription drug treatment involves\u00a0an array of drug classes, including, but not limited to, serotonin reuptake inhibitors (SSRIs), anxiolytics\/benzodiazepines, mood stabilizers, and atypical antipsychotics. Although the borderline personality disorder drug market is extensively genericized, the range of symptoms experienced by patients with borderline personality disorder, together with patients\u2019 heterogeneous responses to treatment, has yielded a complex treatment algorithm in which even brand-only therapies may be\u00a0used, albeit often\u00a0as later-line therapies. In\u00a0this report, we use\u00a0national patient-level claims data to explore the use of key therapies for borderline personality disorder\u00a0in both newly diagnosed and recently treated patients.<\/p>\n
Questions answered<\/strong><\/p>\n Product Description<\/strong><\/p>\n Treatment Algorithms: Claims Data Analysis <\/em>provides detailed analysis of brand use across different lines of therapy using real-world patient-level claims data so that clients can accurately assess their source of business and quantify areas of opportunity for increasing their brand share.<\/p>\n Markets covered:<\/strong> United States<\/p>\n Real-world data: <\/strong>Longitudinal patient-level claims data analysis<\/p>\n Key companies: <\/strong>Allergan, Janssen,\u00a0Sunovion<\/p>\n Key drugs: <\/strong>Invega Trinza, Latuda, Viibryd, aripiprazole, bupropion, escitalopram, anxiolytics\/benzodiazepines, antiepileptic drugs, sertraline<\/p>\n Key analysis provided:<\/strong><\/p>\n\n
\n